Literature DB >> 10052875

The management of PSA failure after radical radiotherapy for localized prostate cancer.

C C Parker1, D P Dearnaley.   

Abstract

An asymptomatic rising serum prostate-specific antigen (PSA) level is the most common form of failure after radical radiotherapy for localized prostate cancer, but there is no consensus as to how it should be managed. This review addresses the following three questions concerning men with PSA failure after radiotherapy: (i) what is the course of the disease without further intervention?; (ii) what is the role of radical treatment, such as salvage prostatectomy?; and (iii) should androgen deprivation be started immediately or should it be delayed until clinical progression occurs? An algorithm for the management of PSA failure after radical radiotherapy for localized prostate cancer is proposed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10052875     DOI: 10.1016/s0167-8140(98)00107-8

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

Review 1.  Hormone therapy for radiorecurrent prostate cancer.

Authors:  H Payne; A Khan; S Chowdhury; R Davda
Journal:  World J Urol       Date:  2012-09-21       Impact factor: 4.226

2.  Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial.

Authors:  Antoine Kass-Iliyya; Gordana Jovic; Claire Murphy; Cyril Fisher; Isabel Syndikus; Chakiath Jose; Christopher D Scrase; John D Graham; David Nicol; Matthew R Sydes; David Dearnaley
Journal:  Eur Urol       Date:  2018-01-04       Impact factor: 20.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.